Boehringer Ingelheim, the $17-billion German pharma major that set up a subsidiary in India three years back, has decided to adopt a partnership model to tap the domestic market.

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>The company is exploring collaborative research options. It will launch its entire research portfolio in the country, said Managing Director J

Boehringer seeks allies to tap local mart

Also Read

US FDA to set up Indian offices by `09

<B>Q&A:</B> Davinder Singh Brar

`Rivals, brokers were behind Ranbaxy`s share price crash`

`I am not a businessman trying to build a hospital`

One-month relief for Ranbaxy

Explore News